Prestige Consumer Healthcare Inc.

Equities

PBH

US74112D1019

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-04-18 pm EDT 5-day change 1st Jan Change
68.35 USD +0.47% Intraday chart for Prestige Consumer Healthcare Inc. -1.21% +11.65%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Prestige Consumer Healthcare Insider Sold Shares Worth $1,766,665, According to a Recent SEC Filing MT
Prestige Consumer Healthcare Insider Sold Shares Worth $2,051,874, According to a Recent SEC Filing MT
Prestige Consumer Healthcare Insider Sold Shares Worth $368,184, According to a Recent SEC Filing MT
Prestige Consumer Healthcare's Fiscal Q3 Earnings, Revenue Increase; Raises 2024 Earnings Guidance; Shares Gain MT
Transcript : Prestige Consumer Healthcare Inc., Q3 2024 Earnings Call, Feb 08, 2024
North American Morning Briefing : S&P 500 to Open -2- DJ
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Reports Q3 Revenue $282.7M, vs. Street Est of $280.4M MT
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Reports Q3 EPS $1.06, vs. Street Est of $1.04 MT
Prestige Consumer Healthcare Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Prestige Consumer Healthcare Inc. Revises Earnings Guidance for the Year of Fiscal 2024 CI
Prestige Consumer Healthcare Unit Recalls 2 Lots of Ting Antifungal Spray Liquid on High Levels of Benzene MT
Prestige Consumer Healthcare Unit Recalls One Lot of Anesthetic Spray Due to Benzene Presence MT
Prestige Consumer Healthcare Unit Recalls 2 Lots of Antifungal Spray Powder Due to High Levels of Benzene MT
Transcript : Prestige Consumer Healthcare Inc., Q2 2024 Earnings Call, Nov 02, 2023
Prestige Consumer Healthcare Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Posts Q2 Revenue $286.3M, vs. Street Est of $285.2M MT
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Reports Q2 EPS $1.07, vs. Street Est of $1.07 MT
Prestige Consumer Healthcare Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024 CI
Prestige Consumer Healthcare Insider Sold Shares Worth $149,657, According to a Recent SEC Filing MT
Transcript : Prestige Consumer Healthcare Inc. Presents at Barclays Global Consumer Staples Conference 2023, Sep-07-2023 03:00 PM
Insider Sell: Prestige Consumer Healthcare MT
Transcript : Prestige Consumer Healthcare Inc., Q1 2024 Earnings Call, Aug 03, 2023
Prestige Consumer Healthcare Fiscal Q1 Earnings Fall, Revenue Rises; Fiscal-Year 2024 Outlook Reaffirmed MT
Tranche Update on Prestige Consumer Healthcare Inc.'s Equity Buyback Plan announced on May 4, 2023. CI
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Reports Q1 Revenue $279.3M, vs. Street Est of $278.4M MT
Chart Prestige Consumer Healthcare Inc.
More charts
Prestige Consumer Healthcare Inc. is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club and e-commerce stores in North America (the United States and Canada) and in Australia and certain other international markets. The Company operates through two segments: North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands include Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart treatments, Little Remedies pediatric over-the-counter products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment, Debrox earwax remover, and others.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
68.35 USD
Average target price
74.33 USD
Spread / Average Target
+8.75%
Consensus
  1. Stock Market
  2. Equities
  3. PBH Stock
  4. News Prestige Consumer Healthcare Inc.
  5. Prestige Consumer Healthcare Earnings Decline, Revenue Rises for Q1 of Fiscal 2023